HEALTH

Carter-Wallace to Retrench: Faced with the collapse of profits from two of its key drugs, the New York-based company said it will slash its pharmaceutical research and sales staffs and curtail manufacturing. The use of the drugs--Felbatol, an epilepsy medication suspected in 11 deaths, and Organidin, an asthma treatment pulled from the market in June--was called into question by the Food and Drug Administration. Analysts said Carter-Wallace Inc. may eventually get out of prescription drugs altogether, leaving its future to consumer products.